Tech Company Financing Transactions
GelMEDIX Funding Round
Safar & Partners, Beacon Angels and Boston Harbor Angels participated in a $13 million Seed funding round for GelMEDIX. The financing was announced on 2/17/2026.
Transaction Overview
Company Name
Announced On
2/17/2026
Transaction Type
Venture Equity
Amount
$13,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to advance the company's lead program, GMX-101, a retinal pigment epithelial (RPE) cell therapy to treat late-stage Geographic Atrophy (GA).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
238 Main St, 5th Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
GelMEDIX is developing therapies that restore vision loss by regenerating damaged retinal cells and preserving the essential structures required for sight. Our groundbreaking biomaterials technology has unlocked a new approach to optimize the delivery, efficacy, and safety of cell and gene therapies. GelMEDIX programs are based on our proprietary injectable hydrogel scaffold that we have engineered to improve the functional replacement and integration of therapeutic cells and the delivery of gene therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Max Cotler
Chief Technical Officer
Noel Vera-Gonzalez
Browse more venture capital transactions:
Prev: 2/17/2026: Render venture capital transaction
Next: 2/17/2026: Moab venture capital transaction
Share this article
News on VC Transactions
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs